AMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Financial guidance reissued to include EBITDA-positive projection for second-half 2020

Strategic shift and momentum build through recent business development activities

Brian Piekos promoted to Chief Financial Officer

Conference call scheduled for 8:00 a.m. ET today

WALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the second quarter ended June 30, 2020. The company reported total revenues for the second quarter of 2020 of $52.8 million, including revenue of $29.6 million from Feraheme® (ferumoxytol injection) and revenue of $22.3 million from Makena® (hydroxyprogesterone caproate injection). The company also reported an operating loss of $7.0 million and an adjusted EBITDA loss of $1.7 million in the second quarter of 2020.1

“Amidst the unprecedented uncertainty that COVID-19 placed on the healthcare system and our economy, AMAG’s marketed therapeutics performed well in the second quarter due in part to our teams’ ability to adapt in a rapidly-changing environment,” said Scott Myers, AMAG’s Chief Executive Officer. “Over the past three months, we have advanced the company’s strategic evolution by reaching important milestones that include a strategic, ex-US partnership with Norgine to further progress ciraparantag and strengthen our company’s ability to invest in our pipeline. We have also streamlined expenses by completing the divestment of Intrarosa® and Vyleesi® and making changes to our portfolio designed to further focus on programs with the highest potential to deliver innovative treatments for patients and unlock shareholder value.”

Please click here to read the full release.